Skip to main content

Advertisement

SpringerLink
Log in

A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial

  • Phase II Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

Background/Patients and methods: 16 adult patients with untreated measurable locally advanced or metastatic inoperable soft tissue sarcoma were treated with oral perifosine, a synthetic alkylphospholipid, believed to inhibit MAP kinase (MAP-K), protein kinase C (PKC), Akt and other regulatory proteins. Perifosine was administered orally in cycles for 21 days out of 28. Loading doses were given day 1 each cycle (900 mg cycle 1, 300 mg cycle 2+) and 150 mg daily was given days 2–21 of each cycle. Cycles were repeated until disease progression, unacceptable toxicity or patient refusal. Results: Seventeen patients were enrolled; 16 and 15 were evaluable for toxicity and response, respectively. A total of 30 cycles of perifosine were administered. Most toxic effects were grade 1 or 2 and commonly included nausea, vomiting, diarrhea, and fatigue (≥40%). Hematologic toxicity was generally mild. There were no significant biochemical abnormalities due to the drug reported. There were 4 serious adverse events (SAE)—none of which was related to perifosine. No objective responses were seen; 4 patients had stable disease for 1.3 to 8.2 months and the remainder of the patients had progressive disease.Conclusions: Perifosine when given according to this dosing schedule does not show evidence of activity in a mixed population of adult soft tissue sarcoma patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bramwell VH, Anderson D, Charette ML, Sarcoma Disease Site G (2003) Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft tissue sarcoma. Cochrane Database of Systematic Reviews (3):CD003293

  2. Verma S, Bramwell V (2002) Dose-intensive chemotherapy in advanced adult soft tissue sarcoma. Exp Rev Anticancer Ther 2(2):201–215

    Article  PubMed  CAS  Google Scholar 

  3. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, Fletcher JA, Silverman SG, Silberman SL, Capdeville R, Kiese B, Peng B, Dimitrijevic S, Druker BJ, Corless C, Fletcher CDM, Joensuu H (2002) Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 347(7):472–480

    Article  PubMed  CAS  Google Scholar 

  4. Maki RG, Awan RA, Dixon RH, Jhanwar S, Antonescu CR (2002) Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. International J Cancer 100(6):623–626

    Article  CAS  Google Scholar 

  5. McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA (2005) Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib target exploration consortium study B2225. J Clin Oncol 23(4):866–873

    Article  PubMed  CAS  Google Scholar 

  6. Verweij J, Van Oosterom A, Blay JY, Judson I, Rodenhuis S, Van Der Graaf W, Radford J, Le Cesne A, Hogendoorn PCW, Di Paola ED, Brown M, Nielsen OS (2003) Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target: Results from an EORTC Soft Tissue and Bone Sarcoma Group phase II study. Europ J Cancer 39(14):2006–2011

    Article  PubMed  CAS  Google Scholar 

  7. Uberall F, Oberhuber H, Maly K, Zaknun J, Demuth L, Grunicke H (1991) Hexadecylphosphocholine inhibits inositol phosphate formation and protein kinase C activity. Cancer Res 51(3):807–812

    PubMed  CAS  Google Scholar 

  8. Ruiter GA, Zerp SF, Bartelink H, Van Blitterswijk WJ, Verheij M (1999) Alkyl-lysophospholipids activate the SAPK/JNK pathway and enhance radiation-induced apoptosis. Cancer Res 59(10):2457–2463

    PubMed  CAS  Google Scholar 

  9. Kondapaka SB, Singh SS, Dasmahapatra GP, Sausville EA, Roy KK (2003) Perifosine, a novel alkylphospholipid, inhibits protein kinase B activation. Mol Cancer Ther 2(11):1093–103

    PubMed  CAS  Google Scholar 

  10. Cuadrado A, Issing W, Fleming TP, Molloy CJ (1994) Uneven distribution of protein kinase C-alpha and -beta isozymes in human sarcomas and carcinomas. J Cell Physiol 159(3):434–440

    Article  PubMed  CAS  Google Scholar 

  11. Issing WJ, Wustrow TP (1991) Overexpression of protein kinase-C-isoenzymes in human tumor cell lines. Laryngo-Rhino-Otologie 70(3):146–150

    Article  PubMed  CAS  Google Scholar 

  12. Unger C: Study D-21266-3040 AOI Phase I study Group. Unpublished data

  13. Unger C: Study D-21266-3087. Weekly enteric coated tablets. AOI Phase I study Group. Unpublished data

  14. Crul M, Rosing H, De Klerk GJ, Dubbelman R, Traiser M, Reichert S, Knebel NG, Schellens JHM, Beijnen JH, Ten Bokkel Huinink WW (2002) Phase I and pharmacological study of daily oral administration of perifosine (D-21266) in patients with advanced solid tumours. Europ J Cancer 38(12):1615–1621

    Article  PubMed  CAS  Google Scholar 

  15. Monga M, Messmann R, Headlee D, Woo EW, Figg WD, Murgo A, Sausville EA: A Phase I trial of oral perifosine in patients with refractory neoplasms: ASCO, 2002, pp #1837

  16. Van Ummersen L, Binger K, Volkman J, Marnocha R, Tutsch K, Kolesar J, Arzoomanian R, Alberti D, Wilding G (2004) A phase I trial of perifosine (NSC 639966) on a loading dose/maintenance dose schedule in patients with advanced cancer. Clin Cancer Res 10(22):7450–7456

    Article  PubMed  CAS  Google Scholar 

  17. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, Van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. J National Cancer Inst 92(3):205–216

    Article  PubMed  CAS  Google Scholar 

  18. Zee B, Melnychuk D, Dancey J, Eisenhauer E (1999) Multinomial phase II cancer trials incorporating response and early progression. J Biopharm Statist 9(2):351–363

    Article  PubMed  CAS  Google Scholar 

  19. Freidlin B, Dancey J, Korn EL, Zee B, Eisenhauer E (2002) Multinomial Phase II Trial Designs. J Clin Oncol 20(2):599

    PubMed  Google Scholar 

  20. Patel V, Lahusen T, Sy T, Sausville EA, Gutkind JS, Senderowicz AM (2002) Perifosine, a novel alkylphospholipid, induces p21(WAF1) expression in squamous carcinoma cells through a p53-independent pathway, leading to loss in cyclin-dependent kinase activity and cell cycle arrest. Cancer Res 62(5):1401–1409

    Google Scholar 

  21. Ruiter GA, Zerp SF, Bartelink H, Van Blitterswijk WJ, Verheij M (2003) Anti-cancer alkyl-lysophospholipids inhibit the phosphatidylinositol 3-kinase-Akt/PKB survival pathway. Anti Cancer Drugs 14(2):167–173

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. British Columbia Cancer Agency, 600 West 10th Avenue, Vancouver, BC, V5Z 4E6

    M. Knowling

  2. Mount Sinai Hospital, Toronto, ON

    M. Blackstein

  3. Juravinski Cancer Centre, Hamilton, ON

    R. Tozer

  4. Tom Baker Cancer Centre, Calgary, AB

    V. Bramwell

  5. CTEP, NCI US, Bethesda, MD

    J. Dancey

  6. NCIC Clinical Trials Group, Kingston, ON

    N. Dore, S. Matthews & E. Eisenhauer

Authors
  1. M. Knowling
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. Blackstein
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. Tozer
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. V. Bramwell
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J. Dancey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. N. Dore
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. S. Matthews
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. E. Eisenhauer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Knowling.

Additional information

Grant Support: Supported by a research grant form the National Cancer Institute of Canada with funds from the Canadian Cancer Society.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Knowling, M., Blackstein, M., Tozer, R. et al. A phase II study of perifosine (D-21226) in patients with previously untreated metastatic or locally advanced soft tissue sarcoma: A National Cancer Institute of Canada Clinical Trials Group trial. Invest New Drugs 24, 435–439 (2006). https://doi.org/10.1007/s10637-006-6406-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10637-006-6406-7

Keywords

Search

Navigation